Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316314 | 0.86 | HSD17B10 (0.50) | TSHROPRK1HSD17B10CNR2ALDH1A1 | |
| SCHEMBL29457453 | 0.84 | OPRK1 (0.49) | OPRK1HSD17B10 | |
| SCHEMBL8125788 | 0.84 | NNMT (0.46) | OPRK1HSD17B10CNR2ALDH1A1HPGD | |
| SCHEMBL9954416 | 0.84 | HSD17B10 (0.49) | TSHROPRK1HSD17B10CNR2ALDH1A1 | |
| Lithium SCHEMBL9954426 | 0.84 | HSD17B10 (0.49) | TSHROPRK1HSD17B10CNR2ALDH1A1 | |
| SCHEMBL757419 | 0.84 | OPRK1 (0.49) | OPRK1HSD17B10 | |
| SCHEMBL11875941 | 0.84 | CNR2 (0.38) | OPRK1HSD17B10CNR2NPC1RAB9A | |
| SCHEMBL2628512 | 0.83 | CNR2 (0.37) | OPRK1HSD17B10CNR2NPC1RAB9A | |
| Lithium Ion SCHEMBL9954420 | 0.83 | CNR2 (0.37) | OPRK1HSD17B10CNR2NPC1RAB9A | |
| SCHEMBL10473684 | 0.82 | CNR2 (0.40) | HTTTSHROPRK1HSD17B10CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022224924-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AGRICULTURAL AND HORTICULTURAL ANTI-BACTERIAL AGENT, NEMATICIDE, AND ANTI-FUNGAL AGENT FOR MEDICAL AND VETERINARY USES | 日本曹達株式会社 | 2022-10-27 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2016126085-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 비욘드바이오주식회사 | 2016-08-11 | — | — | WO | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | HTT 255/4885TSHR 4434/4885PTGDR2 1034/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | HTT 469/4885TSHR 4135/4885PTGDR2 883/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | HTT 1868/4885TSHR 517/4885PTGDR2 37/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | HTT 1868/4885TSHR 517/4885PTGDR2 37/4885 |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, HAVCR2, EIF2AK2 | HTT 1807/4885TSHR 4266/4885PTGDR2 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.